Scientists at TSRI and Synthorx Create the First Semi-Synthetic Organism to Encode and Translate Expanded Genetic Information into a Novel Protein with Different Non-natural Amino Acids
A synthetic DNA base pair expands the genetic alphabet to enable the creation and scale-up of novel and diverse protein therapeutics with improved safety and efficacy profiles
SAN DIEGO, November 29,...
Laura Shawver, Ph.D., Appointed CEO of Synthorx
SAN DIEGO, November 27, 2017 -- Synthorx Inc. announced today that Laura Shawver, Ph.D., was appointed president, chief executive officer (CEO), and director of Synthorx. Dr. Shawver brings many years...
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
SAN DIEGO, August 14, 2017 -- /PRNewswire/ -- Synthorx Inc., a biotechnology company using synthetic biology to discover and develop novel protein therapeutics, announced today the appointment of Marcos Milla,...
Synthorx Announces $10 Million Series B Financing to Develop and Scale Novel Protein Therapeutics with Improved Pharmacological Properties
SAN DIEGO, July 20, 2016 -- /PRNewswire/ -- Synthorx Inc. announced today the completion of a $10 million Series B financing, led by RA Capital Management and joined by Series...
Synthorx Advances Its Synthetic DNA Technology To Make Its First Full-Length Proteins Incorporating Novel Amino Acids
Synthorx’s synthetic DNA base pair expands the DNA alphabet to enable the creation of more diverse proteins for wide variety of applications in medicine and technology
SAN DIEGO, August 19, 2015...
In The News
Top News: Synthorx Co-founder Creates Stable Semi-Synthetic Organism
Synthorx co-founder, Floyd Romesberg, Ph.D. and colleagues have created a single-cell organism that can stably maintain a synthetic DNA base pair. The research was published in PNAS.
BioWorld Insight: Taking Novel Drug Development to the Next Level
BioWorld Insight interviewed Synthorx CEO, Court Tuner, to discuss how synthetic biology is being used to take drug development to the next level.
To develop improved drugs, Synthorx is using the...
Synthorx Co-founder, Dr. Floyd Romesberg Presents at TEDMED
Developing the Expanded Genetic Code: G.C.A.T. Those four letters have been the world’s genetic vocabulary since the beginning of life on earth, that is, until Dr. Floyd Romesberg and his team created X and Y.
MIT Technology Review: Startup’s Artificial DNA Could Revolutionize Drug Design
MIT Technology Review interviewed Synthorx president and CEO, Court Turner, to discuss how the company is pursuing breakthrough medicines with proteins unlike any seen in nature.
Proteins are formed by stringing...
Top News: Synthorx Raises $10 Million to Develop and Scale Novel Protein Therapeutics with Improved Pharmacological Properties
In July 2016, Synthorx announced the completion of a $10 million Series B financing, led by RA Capital Management and joined by Series A investors Avalon Ventures and Correlation Ventures. (
We will be announcing upcoming events shortly.